CVS Health faces a regulatory setback as the Trump administration put forward a Medicare Advantage rate increase of just 0.09% for 2027, well below the 4%–6% boost analysts had anticipated. This program accounts for more than one-third of CVS’s total revenue through its Aetna benefits segment, and the negligible adjustment heightens pressure on already thin single-digit operating margins. Rising medical costs have eroded profitability in recent quarters, and without a meaningful bump in reimbursement rates, investors will be watching closely to see whether CVS can offset these headwinds through cost controls or leverage in its retail pharmacy operations. Despite a 77% gain in the stock during 2025, the company’s valuation discounts the risk of margin compression in its health benefits business.

BI Asset Management Fondsmaeglerselskab A S reduced its holdings in CVS Health by 30.1% during the third quarter, selling 166,058 shares to leave a position of 386,062 shares valued at approximately $27.5 million. In contrast, Savant Capital LLC increased its stake by 33.5% to 73,762 shares, Unison Advisors LLC added 547 shares to reach 55,411, J.W. Cole Advisors Inc. lifted its holding by 7.5% to 26,407 shares, Envestnet Asset Management Inc. grew its position by 2.6% to 1,990,902 shares (roughly $150.1 million), and Marco Investment Management LLC added 1,805 shares for a total of 76,236. Institutional and hedge fund ownership now stands at 80.66%. Separately, CVS recently paid a quarterly dividend of $0.665 per share on February 2, representing a $2.66 annualized payout and a 3.5% yield, with a reported payout ratio of 700%.